Overview

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated non-triple-negative metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib